PDCD1 and neoplasm: In comparison, PD-1-0520 exhibited micromolar IC50 values in A375 and HCT116 cells and achieved 68% tumor inhibition at 10 mg/kg in vivo, suggesting that its biological performance is competitive within the landscape of peptide-based immune checkpoint inhibitors.